Aytu BioPharma (AYTU) Earnings Date, Estimates & Call Transcripts $2.38 -0.02 (-0.83%) (As of 12:40 PM ET) Add Compare Share Share Earnings Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 12EstimatedActual EPS (Sep. 26) -$0.82 Missed By -$0.37 Consensus EPS (Sep. 26) -$0.45 Conference Call Transcript Get Aytu BioPharma Earnings AlertsEnter your email address below to receive the latest news and earnings results for AYTU and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueAYTU Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AYTU Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the MarketsNOTICE: You have until Tuesday, November 19thOn Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> AYTU Earnings Date and InformationAytu BioPharma last announced its earnings data on September 26th, 2024. The reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by $0.37. The business had revenue of $17.98 million for the quarter. Aytu BioPharma has generated ($2.63) earnings per share over the last year (($2.63) diluted earnings per share). Aytu BioPharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off prior year's report dates.Read More Aytu BioPharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/12/2024(Estimated)------- 9/26/2024Q4 2024($0.45)($0.82)($0.37)($0.82)-$17.98 million 5/15/2024Q3 2024($0.64)($0.52)+$0.12($0.52)-$17.99 million2/14/2024Q2 2024-($0.04)($0.04)($0.04)-$22.93 million11/14/2023Q1 2024-($1.48)($1.48)($1.48)-$22.10 million9/27/2023Q4 2023-$0.16+$0.16$0.91-$30.73 million5/11/2023Q3 2023-($1.93)($1.93)($1.93)-$22.73 millionTrade Alongside Pelosi, Buffett, and More (Ad)People don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, Bill Ackman, Steve Cohen and more. They also don’t know that they can learn how it’s done and receive daily, AI powered trade alerts for free! All because of one trading veteran that set up a free newsletter designed to level the playing field.Sign up takes less than 10 seconds, and you’ll start getting his alerts and market insights absolute2/21/2023Q2 2023$0.20($1.31)($1.51)($0.47)$32.60 million$26.28 million11/14/2022Q1 2023-($1.20)($1.20)($1.20)-$27.66 million9/27/2022Q4 2022($0.24)($0.25)($0.01)($0.01)$25.70 million$27.45 million5/16/2022Q3 2022($0.41)($0.27)+$0.14$1.25$24.20 million$24.20 million2/13/2022Q2 2022($0.58)($0.44)+$0.14($0.44)-$23.13 million11/15/2021Q3 2021($0.49)($1.09)($0.60)$0.43-$21.90 million 9/26/2021Q2 2021($0.49)($0.75)($0.26)($0.53)$24.50 million$23.48 million 5/16/2021Q1 2021($0.36)($1.41)($1.05)$1.07$14.10 million$13.48 million 2/10/2021Q4 2020($0.44)($0.70)($0.26)($0.22)$11.80 million$15.15 million 11/17/2020Q3 2020($0.06)($0.04)+$0.02($0.04)$13.70 million$13.52 million 5/14/2020Q3($0.22)($0.15)+$0.07($0.15)$7.00 million$8.16 million 2/13/2020Q2 2020($0.34)($0.31)+$0.03($0.61)$2.73 million$3.18 million11/14/2019Q1($0.30)($0.32)($0.02)($0.32)$1.45 million$1.44 million Aytu BioPharma Earnings - Frequently Asked Questions When is Aytu BioPharma's earnings date? Aytu BioPharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates. Learn more on AYTU's earnings history. Did Aytu BioPharma beat their earnings estimates last quarter? In the previous quarter, Aytu BioPharma (NASDAQ:AYTU) missed the analysts' consensus estimate of ($0.45) by $0.37 with a reported earnings per share (EPS) of ($0.82). Learn more on analysts' earnings estimate vs. AYTU's actual earnings. How can I read Aytu BioPharma's conference call transcript? The conference call transcript for Aytu BioPharma's latest earnings report can be read online. Read Transcript How much revenue does Aytu BioPharma generate each year? Aytu BioPharma (NASDAQ:AYTU) has a recorded annual revenue of $81.00 million. How much profit does Aytu BioPharma generate each year? Aytu BioPharma (NASDAQ:AYTU) has a recorded net income of -$17.05 million. AYTU has generated -$2.63 earnings per share over the last four quarters. More Earnings Resources from MarketBeat Related Companies: ZIVO Earnings SCYX Earnings CELU Earnings AVTE Earnings ATNM Earnings ANEB Earnings MURA Earnings THTX Earnings TCRT Earnings TCBP Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Nike’s Post-Earnings Drop Presents a Buying OpportunityMicron Stock Soars as AI Demand Fuels Big Q4 Earnings BeatGameStop: Earnings Won’t Save It, Dilution Points to TroubleIs Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season? This page (NASDAQ:AYTU) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | SponsoredKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
